Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.
Cancer Sci. 2022 Oct;113(10):3510-3517. doi: 10.1111/cas.15496. Epub 2022 Aug 12.
Urothelial carcinoma (UC) is an umbrella term for bladder cancers (BCa) and upper-tract urothelial carcinoma (UTUC), with BCa and UTUC sometimes detected concomitantly. The methods of detection for UC are often inaccurate or highly invasive, and, therefore, are thought to be unsatisfactory. Previously, we reported seven serum miRNAs as diagnostic markers for BCa. Here, we re-evaluated potential diagnostic miRNAs in different institutions. We prospectively analyzed serum samples obtained from 126 UC patients (BCa: 106 samples; UTUC: 14 samples; UTUC with BCa: six samples) and 50 noncancer controls by microarray analysis. We randomly assigned these samples into a training or a validation set. Biomarker candidate miRNAs were selected based on cross-validation scores in the training set of samples, with diagnostic power confirmed in the validation set. Among the diagnostic miRNAs identified in this way, miR-1343-5p and miR-6087 had been identified as potential diagnostic miRNAs in our previous study. In addition, we evaluated the association between the serum levels of identified miRNAs and the presence of UC risk conditions. The expression levels of several miRNAs correlate with the risk factors in participants without UC, which may be explained by the presence of a microscopic tumor or a precancerous lesion. In conclusion, we identified two robust miRNA diagnostic markers for UC detection. Further functional analysis is required to elucidate the mechanism by which alterations in the expression of these miRNAs occur.
尿路上皮癌 (UC) 是膀胱癌 (BCa) 和上尿路尿路上皮癌 (UTUC) 的统称,BCa 和 UTUC 有时同时被检测到。UC 的检测方法通常不准确或具有高度侵袭性,因此被认为不理想。此前,我们报道了七种血清 miRNA 作为 BCa 的诊断标志物。在这里,我们在不同机构重新评估了潜在的诊断 miRNA。我们通过微阵列分析前瞻性地分析了 126 例 UC 患者(BCa:106 例;UTUC:14 例;UTUC 伴 BCa:6 例)和 50 例非癌症对照者的血清样本。我们随机将这些样本分配到训练集或验证集中。基于训练集样本中的交叉验证分数选择候选 miRNA 标志物,并在验证集中确认诊断能力。通过这种方式鉴定的诊断 miRNA 中,miR-1343-5p 和 miR-6087 已在我们之前的研究中被鉴定为潜在的诊断 miRNA。此外,我们评估了鉴定的 miRNA 血清水平与 UC 风险状况之间的关联。在没有 UC 的参与者中,几种 miRNA 的表达水平与风险因素相关,这可能是由于存在微小肿瘤或癌前病变。总之,我们确定了两种用于 UC 检测的稳健 miRNA 诊断标志物。需要进一步的功能分析来阐明这些 miRNA 表达变化发生的机制。